Risk of Cognitive Decline Associated With Paroxetine Use in Elderly Nursing Home Patients With Depression

Objective:

This study evaluated the risk of cognitive decline associated with paroxetine use in elderly nursing home patients with depression.

Methods:

A retrospective cohort study was conducted using the 2007 to 2010 Medicare Part D claims and minimum data set (MDS) data involving new users of paroxetine and other selective serotonin reuptake inhibitors (SSRIs). The primary outcome was MDS Cognition Scale. The repeated-measures mixed model was used to examine the effect of paroxetine on cognition after controlling for other factors.

Results:

The baseline MDS Cognition Scale measures for paroxetine (n = 63) and other SSRI users (n =1018) were 2.02 (±1.85) and 2.50 (±2.39), respectively. The repeated-measures mixed model did not find statistically significant difference in cognition with the use of paroxetine (β = 0.02, 95% CI: –0.16 to 0.21]) when compared to other SSRIs.

Conclusions:

There was no differential effect of paroxetine on cognition when compared to other SSRIs.

Risk of Cognitive Decline Associated With Paroxetine Use in Elderly Nursing Home Patients With DepressionRisk of Cognitive Decline Associated With Paroxetine Use in Elderly Nursing Home Patients With DepressionAlzheimers{$excerpt:n}